It targets NOS3 and VEGFA and is associated with multiple AD core phenotypes including abnormal long-term potentiation, abnormal synaptic transmission, astrocytosis, gliosis, and neuron degeneration (see Supplement_S2). Here, NOS3 is linked to Alzheimer disease.